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In patients with chronic heart failure (CHF), erythropoietin (Epo) levels are increased 
and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak 
correlation with haemoglobin (Hb) levels.
Methods
This is a retrospective analysis of a subgroup of the OPTIMAAL trial in which serum 
Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients 
with an acute myocardial infarction (AMI) complicated by signs or symptoms of 
heart failure. We investigated the determinants and the prognostic role of elevated Epo 
levels in these patients and we studied the change in Epo levels by either captopril or 
losartan.
results 
The correlation between Epo and Hb at baseline (r=-0.348;p<0.001) and after 1 month 
(r=-0.272;p<0.001) disappeared after 1 year of follow up (r=-0.129;p=0.102). 
At 1 year, CRP was the only factor associated with Epo levels. Higher Epo levels at 
baseline were independently related to a higher mortality during 2-years follow-up 
(Hazard Ratio 2.84;p=0.014). In the captopril group, logEpo levels decreased from 
1.19(±0.26) to 0.95(±0.20) mlU/ml and in the losartan group from 1.19(±0.27) 
to 1.01(±0.17) mlU/ml (p=0.036 between groups). 
Conclusion
In this substudy of the OPTIMAAL trial, the correlation between Epo and Hb disap-
peared in early post AMI heart failure patients. Furthermore, elevated Epo levels at 
baseline predicted increased mortality. 




In patients with chronic heart failure (CHF), erythropoietin (Epo) levels are often in-
creased and related to a poor prognosis.1,2,3 In contrast to healthy subjects or patients 
with primary renal disease, elevated Epo levels in CHF patients only show a mild 
correlation with haemoglobin (Hb).2,4,5 This finding seems to be a discrepancy, but 
can be explained by several other conditions besides anaemia influencing Epo levels 
in CHF.6
Epo levels are elevated during the initial phase of an acute myocardial infarction 
(AMI).7,8,9 However, both the changes and determinants of Epo levels from the acute 
phase of an AMI to early post-AMI heart failure are as yet unknown. 
Several investigators suggested a relation between Epo levels and activity of the renin-
angiotensin system. It was demonstrated that angiotensin II increased Epo by stimu-
lating the AT1-receptor,10,11,12 and in smaller studies the use of both Angiotensin Con-
verting Enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARB) have been 
related to a reduction of serum Epo levels.13,14,15,16 This present study is the first to 
evaluate the long term prognostic value of Epo levels in patients who show signs and 
symptoms of heart failure after an AMI. Furthermore, we looked at the determinants 
of Epo levels and we studied the modulation of ACE-inhibition versus ARB on serial 




The OPTIMAAL (Optimal Trial in Myocardial Infarction with Angiotensin II Antago-
nist Losartan) trial compared the effect of the ACE inhibitor captopril (50mg three 
times daily) and the ARB losartan (50mg daily) on all cause mortality in patients 
with an AMI who showed signs or symptoms of heart failure within the first 10 days 
of hospitalisation.17 The primary endpoint was all-cause mortality. The background, 
rationale and results of the main study were previously described.18 
The present study analyses the data of the prospectively designed neurohormonal 
substudy of the OPTIMAAL. Baseline characteristics of 224 patients in the substudy 
were similar to those of the OPTIMAAL in most aspects. However, in the OPTIMAAL 
main trial more patients had a history of dyslipidemia or CHF, more were in Killip 
Class I, more were diabetic and less used a statin.19 Blood samples of routine labora-
tory measurements, Epo, N-terminal pro B-type natriuretic peptide (NTproBNP) and 
C-reactive protein (CRP) were obtained at 4 time points: baseline (days 1-10, median 
day 3), 30 days, 1 year and at 2 years after AMI. 
Blood sampling
Blood samples were collected using pyrogen-free tubes containing EDTA (Becton 
Dickinson. San Jose, CA) and were immediately centrifuged at 2000g for 30 minutes 
at 4°C. The platelet poor plasma was separated and stored at -80°C until analysis. 
Plasma Epo levels were measured using the IMMULITE EPO assay (Diagnostic Prod-
ucts Corporation (DPC), Los Angeles, California), which has been described before.20 
The DPC assay consists of a ligand-labeled monoclonal anti-Epo capture antibody, an 
alkaline phosphatase-labeled polyclonal conjugate antibody, and solid-phase anti-li-
gand–coated polystyrene beads. The amount of plasma Epo was quantified by chemi-
luminescent measurement in a luminometer. 
NTproBNP in plasma was determined by an immunoassay, as described previously.16  
A noncompetitive assay was used with the capture antibody directed to the C-terminal 
of human N-BNP and the biotinylated N-terminal directed antibody as the detector 
antibody. Quantification of NTproBNP was done by chemiluminescent measurement 
on a Dynatech MLX Luminometer (Dynex Technologies Ltd, Worthington, UK). 
The estimated Glomerular Filtration Rate (eGFR) was calculated using the abbreviated 
MDRD equation: 186 x (Creat / 88.4)-1.154 x (Age)-0.203 (x 0.742 if female). Chronic 
kidney disease (CKD) was defined as eGFR < 60 ml/min/1.73m2.
Statistical analyses
Results are presented as mean ± SD when normal distributed and as median and 
interquartile range (IQR) when non-normal distributed. Normality was tested by 
comparing a histogram of residuals to a normal probability curve. If the distribution 
of the residuals did not resemble the normal distribution, variables were log-trans-
formed. Comparisons of continuous variables between groups were made by un-
paired Student’s t-tests, and, if distributed non-normally, by Mann-Whitney U tests. 
The relationship between Epo and Hb levels was analysed using scatter plots and by 
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calculating Pearson’s correlation coefficients. Linear regression identified univariable 
factors which showed an association with logarithmically transformed Epo levels at 
baseline, at 1 month and at 1 year (p < 0.10). These factors (age, gender, CRP, NT-
proBNP, and Hb) were put into a multivariable model, using a backward stepwise 
selection procedure, in order to identify the predictors of Epo levels. 
A Kaplan-Meier survival plot was constructed with Epo levels dichotomized according 
to the median and the log rank test was performed. The association between param-
eters and mortality was assessed by Cox proportional hazards regression. Univariable 
factors with a trend towards an increased risk of mortality (p < 0.10) were identi-
fied (gender, age, CKD and Hb, NTproBNP, and Epo dichotomized according to their 
median) and were included in a multivariable Cox regression model based on the 
strength of their univariate association. The assumption of proportional hazards was 
checked by comparing the estimated log-minus-log survival curves for parallelism. 
All tests were 2-tailed and a p-value < 0.05 was considered statistically significant. All 
analyses were performed with SPSS for Windows version 14.0.1. (SPSS, Chicago, IL). 
rEsults
patient demographics
Baseline characteristics of patients randomized to either captopril or losartan did not 
differ significantly (Table 1). Mean age was 67.8 ± 10.4 years and 70% of subjects 
was male. During follow up (mean 939 days, range 3-1222), a total of 32 patients 
died (15 in the captopril and 17 in the losartan group). Of these deaths, 13 occurred 
during the first month (7 in the captopril and 6 in the losartan group). Laboratory 
values at each time-point (baseline, 1 month, 1 and 2 years) are presented in Table 2. 
Median Epo levels were 15.4 mlU/ml (IQR 10.3-21.4); (reference range 2.6 to 34 
mlU/ml 20). At baseline, CRP and NT-proBNP were elevated and declined to normal 
values in the first year of follow up. 
Correlation between hb and epo
An inverse correlation between Hb and Epo was found at baseline (r=-0.348; 
p<0.001) and at 1 month (r=-0.272; p<0.001). In contrast, no correlation between 
Hb and Epo was found after 1 year (r=-0.129; p=0.102) and after 2 years of follow 
up (r=-0.152; p=0.063). 
Determinants of epo levels 
Epo levels at 1 month, 1 year and 2 years differed significantly from baseline (p<0.001). 
Table 3 shows the outcomes of a multivariable linear regression analysis for determi-
nants of Epo levels at baseline and at both 1 month and 1 year post infarction. At base-
line, the multivariable regression model showed lower Hb (Beta -0.319; p<0.001) as 
well as higher logNT-proBNP (Beta 0.206; p=0.003) to be independent determinants 
of higher Epo levels. At 1 month, the correlation between Hb and Epo became less 
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pronounced, while at 1 year, no correlation between Hb and Epo was found. At 1 
year, higher Epo levels were predicted by higher CRP levels (Beta 0.209; p=0.006).     
prognostic value of epo levels
Kaplan Meier survival curves demonstrated that higher Epo levels at baseline were re-
lated to an increased mortality in the subsequent follow-up period (Log rank p=0.05; 
Figure 1). For the primary endpoint, multivariable Cox regression analyses demon-
strated that at baseline a higher age (Hazard Ratio (HR) 7.44; p=0.001), CKD (HR 
2.88; p=0.008) and higher logEpo (HR 2.84; p=0.014), were independently associ-
ated with an increased risk of mortality (Table 4). 









Age (yrs) * 67.8 ± 10.4 67.8 ± 10.4 67.8 ± 10.3 0.995
Male 157 (70.1%) 77 (68.8%) 80 (71.4%) 0.662
Smoking 89 (39.7%) 40 (35.7%) 49 (43.8%) 0.219
BMI * 26.0 ± 3.7 25.8 ± 3.5 26.2 ± 3.9 0.473
History     
Hypertension 72 (32.1%) 42 (37.5%) 30 (26.8%) 0.086
AMI 26 (11.6%) 16 (14.3%) 10 (8.9%) 0.211
PTCA 4 (1.8%) 1 (0.9%) 3 (2.7%) 0.313
CABG 3 (1.3%) 2 (1.8%) 1 (0.9%) 0.561
Diabetes 26 (11.6) 16 (14.3%) 10 (8.9%) 0.211
Dyslipidemia 52 (23.2%) 23 (20.5%) 29 (25.9%) 0.342
Atrial Fibrillation 28 (12.5%) 17 (15.2%) 11 (9.8%) 0.225
CHF 5 (2.2%) 3 (2.7%) 2 (1.8%) 0.651
Killip Class
   I  
   II 
   III


















Warfarin 38 (17%) 21 (18.8%) 17 (15.2%) 0.479
Aspirin 216 (96.4%) 107 (95.5%) 109 (97.3%) 0.474
Loop-diuretic 164 (73.2%) 79 (70.5%) 85 (75.9%) 0.368
ß-blocker 169 (75.4%) 88 (78.6%) 81 (72.3%) 0.279
Statin 143 (63.8%) 65 (58%) 78 (69.6%) 0.071
BMI=Body-Mass Index; AMI=Acute Myocardial Infarction; CABG=Coronary Artery Bypass Grafting; 
PTCA=Percutaneous Transluminal Coronary Angioplasty; CHF=Chronic Heart Failure; * Mean±SD
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Table 2. Laboratory values at baseline, at 1 month, and at 1 year and 2 years in patients with heart 
failure after an acute myocardial infarction 
Variable Baseline 1 month 1 year 2 year
Hb (g/dL) * 12.9 ± 1.4 13.7 ± 1.3 13.3 ± 1.4 13.6 ± 1.4
Epo (mlU/ml) § 15.4 (10.3-21.4) 10.5 (7.6-14.7) 9.0 (7.1-12.5) 9.5 (7.4-13.2)
CRP (mg/L) § 49 (22-98) 2.3 (1.2-4.3) 1.7 (1.0-3.2) 1.6 (0.9-3.5)
NT-proBNP (ng/L) § 1034 (613-1647) 645 (377-1033) 323 (138-6567) 310 (137-607)
Creatinine (µmol/L) § 89 (77-102) 93 (86-106) 91 (82-104) 93 (85-108)
CRP=C-Reactive Protein; Hb=Haemoglobin; NTproBNP= N-Terminal pro-B-type Natriuretic Peptide; 
*Mean±SD; §Median (IQR)
Table 3. Independent predictors of (log)erythropoietin levels at baseline, 1 month and at 1 year
LogEpo at baseline LogEpo at one month LogEpo at one year
Variable Beta B (95%CI) p Beta B (95%CI) p Beta B (95%CI) p
Hb (g/dL) -.319 .00 (.00,.00) <0.001 -.201 .00 (.00,.00) 0.014
logNTproBNP
(ng/L)
.206 .21 (.07,.34) 0.003 .179 .12 (.01,.23) 0.029
logCRP (mg/L) .222 .11 (.04,.18) 0.003 .209 0.10 (.03,.16) 0.006
Gender .010 .00 (-.07,.08) 0.883 .050 .03 (.05,.11) 0.519 .165 .07 (.00,.13) 0.034
Age (years) -.072 .00 (.00,.00) 0.303 -.050 .00 (.00,.00) 0.545 .143 .00 (.00,.00) 0.064
CRP=C-Reactive Protein; Hb=Haemoglobin; NTproBNP=N-Terminal pro-B-type Natriuretic Peptide
Days in trial









Epo < median 
Epo > median
Log rank p = 0.05 
Figure 1.
Kaplan Meier survival 




effects of aCe-I and arB on epo levels
At baseline, Epo and Hb levels in both the captopril and the losartan group were similar 
(Table 5). However, after 2 years, Epo levels were significantly lower in the captopril 
treated patients (0.95±0.20 vs 1.01±0.17; p=0.019). In addition, compared to the 
losartan group, Epo reduction from baseline to 2 years was larger in the captopril 
group (p=0.036; Table 5). Multivariable linear regression analyses showed that Hb 
change between baseline and two years (Beta -0.243; p=0.003), age (Beta 0.168; 
p=0.04), and captopril treatment (Beta 0.204; p=0.01) were independent predictors 
of the change in Epo from baseline to 2 years (Table 6). Interestingly, a time-dependent 
analysis of the difference in Epo values from 1 month to 2 years showed that the only 
independent predictor was a change in CRP (Beta 0.332; p<0.001). 
Table 4. Results of a multivariable Cox regression analysis of markers of all cause mortality in patients 
with heart failure after an acute myocardial infarction
Univariable Multivariable
Variable HR (95%CI) p-value HR (95%CI) p-value
High Age* 10.45 (3.2,34.3) <0.001 7.44 (2.2-25.6) 0.001
Gender 1.08 (0.51,2.29) 0.832 2.28 (0.9,5.7) 0.080
CKD 4.43 (2.2,8.9) <0.001 2.88 (1.3,6.3) 0.008
Low Hb* 1.97 (0.94,4.1) 0.071
High logNTproBNP* 2.3 (1.1,4.9) 0.026
High logEpo* 1.90 (0.91,4.0) 0.087 2.84 (1.2,6.5) 0.014
*variables dichotomized according to their median: Age > 68 years; logEpo > 1.02 mlU/mL; Hb < 13.0 g/
dL; logNTproBNP > 3.09 ng/L; CKD=Chronic Kidney Disease; Hb=Haemoglobin; NTproBNP=N-Terminal 
pro-B-type Natriuretic Peptide
Table 5. Difference between baseline and 2 years of follow up of levels of erythropoietin, haemoglobin, 
and eGFR rate between captopril and losartan treated patients.  
Variable Captopril Losartan p-value
logEpo (mlU/ml) baseline* 1.2 ± 0.26 1.2 ± 0.27
logEpo 2 year* 0.95 ± 0.20 1.0 ± 0.18
∆logEpo Bl-2y* -0.26 ± 0.26 -0.17 ± 0.26 p=0.036
Hb (g/dL) baseline* 12.9 ± 1.4 13.0 ± 1.4
Hb 2 year* 13.4 ± 1.4 13.7 ± 1.4
∆Hb Bl-2y 0.54 ± 1.2 0.55 ± 1.1 p=0.928
eGFR (ml/min) baseline* 72.2 ± 18.6 72.5 ± 15.3
eGFR 2 year* 66.9 ± 20.4 68.8 ± 13.7
∆eGFR Bl-2y* -6.56 ± 14.2 -6.12 ± 9.96 p=0.805
Epo=Erythropoietin; Hb=Haemoglobin; eGFR=estimated Glomerular Filtration Rate; 
Bl=Baseline; * Mean ± SD




The present study showed that in patients with signs and symptoms of heart failure 
early after myocardial infarction, the correlation between Epo and Hb disappeared 
during the follow up period. Also, higher Epo levels at baseline predicted increased 
mortality and in addition, treatment with captopril reduced Epo levels to a larger 
extend compared to losartan.    
epo levels after aMI
Laboratory findings showed an initial increase of CRP and NT-proBNP which declined 
to normal values in the first year of follow up. Creatinine levels did not change over 
time. These results reflect the acute phase of an AMI and subsequent early post-AMI 
heart failure with normalisation of laboratory values. 
Epo levels were elevated during the first days after AMI, though still within the nor-
mal range, and declined significantly in the following weeks. The pathophysiological 
mechanisms behind the increase in Epo levels during and after AMI are not well un-
derstood. One explanation is that Epo levels are increased as a response to a decrease 
in Hb due to treatment interventions during an AMI.7 Our current observation that 
baseline Epo levels correlate well with Hb levels supports this hypothesis. Another 
explanation may be that Epo levels are increased due to myocardial hypoxia, as has 
been shown in a mouse myocardial infarction model.21 However, Namiuchi et al.8 
found a relationship between high endogenous Epo levels and smaller infarct sizes, 
which seems to argue against this hypothesis. We and others have repeatedly shown 
that exogenous Epo reduced cardiomyocyte apoptosis and increased angiogenesis and 
capillary density.22,23,24,25,26 However, the present study does not prove that Epo levels 
are causally linked to morbidity and mortality. Although Epo treatment in anaemic 
chronic renal failure patients has raised concerns about the safety of increasing Hb 
to higher levels 27,28, larger randomized clinical trials with Epo treatment in cardiac 
patients are ongoing. 29,30
Table 6. Multivariable linear regression analyses of the change in Epo between baseline and 2 years 
∆ logEpo baseline – 2 years ∆ logEpo 1 month – 2 years 
Variable Beta B (95%CI) p Beta B (95%CI) P
Age (yrs) .168 .00 (.00,0.01) .042 .072 .00(.00,.00) .870
Gender .057 .03(-.06,.12) .472 .033 .02(-.06,.09 .692
Captopril 
treatment
.204 .11 (.03,.19) .010 
∆ Hb (g/dL) -.243 -.06 (-.09,-.02) .003 





Another interesting finding of this present study is that at baseline, a correlation be-
tween Epo and Hb was found, which decreased over time and had disappeared at 1 
year. This observation is in line with previous studies,3,2 and this consistent finding 
implies that in heart failure Epo levels are driven by other factors than anaemia. In 
worsening heart failure, cardiac output decreases and through the significant reduc-
tion in renal blood flow, Epo levels increase. Also, Epo production is influenced by 
chronic inflammation.31 A correlation between high Epo and high CRP levels in CHF 
was previously described by our group32  and is now confirmed in the current study. 
In addition, high Epo levels in CHF could suggest bone marrow resistance to the ef-
fects of endogenous Epo.33 
In summary, from AMI to early post-AMI heart failure, different factors seem to deter-
mine Epo levels at different points in time.
prognostic value of epo      
Our results demonstrated that higher Epo levels were related to increased mortality, 
though interpretations should be made with caution, since the number of events was 
small. This finding is supported by previous findings from our group in a different 
population of patients with CHF.2 Also, in a study with 188 CHF patients, serum Epo 
was a strong predictor of both mortality and heart failure hospitalisation.3 Further-
more, Volpe et al.1 studied Epo levels in 108 CHF patients and found a positive cor-
relation with functional New York Heart Association (NYHA) class. All these studies 
suggest that higher Epo levels are a reflection of disease progression. 
effects of aCe-inhibitors vs arBs on epo levels
Plasma Epo levels were compared between patients who were treated with either cap-
topril or losartan. After 2 years, captopril treatment demonstrated a significantly stron-
ger reduction of Epo levels compared to losartan. Interestingly, this effect was found 
without a parallel change in Hb or kidney function. 
The interaction between Epo and the RAS system is well described.34,35,36,37 CHF pa-
tients often show elevated levels of angiotensin II, a hormone that stimulates eryth-
ropoiesis via the AT-1 receptor. In contrast to ARBs, which block the activation of 
AT-1 receptors, ACE-inhibitors only partially block the formation of angiotensin II. 
In a study with 72 healthy subjects, Freudenthaler et al.10 showed that angiotensin II 
raised Epo levels, a process which losartan, a specific AT-1 receptor antagonist, was 
able to block, and captopril was not. 
The difference in Epo levels between the captopril and losartan treated patients in 
the present study is difficult to explain. Several smaller studies have demonstrated 
that both ACE-inhibitors and ARBs can reduce Epo levels, although conflicting re-
sults have been described. In dilated cardiomyopathy patients, captopril reduced Epo 
levels which correlated with improved clinical and haemodynamic parameters.13 In 
addition, the ARB valsartan reduced Epo levels in CKD patients.16 On the other hand, 
Robles et al.14 showed that in hypertensive patients irbesartan reduced Epo levels in 
contrast to fosinipril, which did not influence Epo levels. And in patients with and 
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without post transplant erythrocytosis, neither enalapril nor losartan treatment had 
an effect on Epo levels.15 In the OPTIMAAL trial, losartan 50 mg once daily was com-
pared to captopril 50 mg three times daily. A trend towards an improved survival of 
the captopril group was seen 18, which could have been a reflection of the low dose of 
losartan that was used. Although highly speculative, this difference might have trans-
lated into different haemodynamic effects that could explain the difference in Epo 
levels. Other explanations might be related to the increased stimulation of the AT2 
receptor with ARBs, the effects of ACE-inhibitors on Ac-SDKP 38 (a strong inhibitor of 
haematopoiesis), or the increase of bradykinin with ACE-inhibitors.39
Limitations
Several limitations of the present study have to be acknowledged. Although labora-
tory parameters in this study do not reflect severe heart failure in these patients, all 
patients that were included did show signs and/or symptoms of heart failure at the 
time of inclusion. Unfortunately, data on heart failure class or left ventricular ejection 
fraction during follow up are lacking. Although after two years the difference in Epo 
levels between captopril and losartan treated patients reached statistical significance, 
these differences are small and may represent chance.   
In conclusion, in patients with early signs or symptoms of heart failure after an AMI, 
the correlation between Epo and Hb disappeared in the post-infarct state. Also, el-
evated Epo levels were independently related to a higher 2-year mortality. Finally, 
captopril reduced Epo levels to a larger extend compared to losartan.
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